Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.
Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.